MRK : Analysis & Opinions

  1. Markets Falling? Get Your Defense Ready

    April 14, 2014
    The stock market is getting whacked. The question now for many investors is, what to do about it. The first thing to ...
  2. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  3. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  4. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  5. AstraZeneca Goes Back To The M&A Well Yet Again

    August 26, 2013
    AstraZeneca's acquisition of Amplimmune could pay big dividends in a decade.
  6. Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook

    July 30, 2013
    Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
  7. Stock Market News for July 15, 2013 - Market News

    July 15, 2013
    Benchmarks posted marginal gains on Friday following better-than-expected results of few banking companies.
  8. Setback for Achillion - Analyst Blog

    July 3, 2013
    Achillion Pharma recently received a setback when the FDA placed a clinical hold on its HCV candidate, sovaprevir after observing ...
  9. Good News for Hospira, Shares up - Analyst Blog

    July 2, 2013
    The EMA's CHMP recommended the approval of Hospira's biosimilar version of Remicade.
  10. Stock Market News for July 1, 2013 - Market News

    July 1, 2013
    Benchmarks ended a three day gaining streak on Friday as fears of the Federal Reserve scaling back the bond buying program ...
  11. Stock Market News for June 27, 2013 - Market News

    June 27, 2013
    Weaker-than-expected GDP numbers eased investor concerns that the Federal Reserve would decrease monetary stimulus in the ...
  12. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  13. After A Good Run, Novartis Looks Fairly Valued

    June 12, 2013
    Novartis is a well-balanced, high-quality pharma with growth credentials, but also a fair valuation today.
  14. Roche, Reloaded

    May 21, 2013
    Roche has one of the best long-term growth profiles in the Big Pharma space
  15. After A Big Rally, Pfizer Might Need Some Rest

    May 21, 2013
    A big rally has brought Pfizer back to fair value.
  16. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  17. The “Healthy” Play In Contract Research Organizations

    April 17, 2013
    The pharmaceutical industry is under pressure to do more with less. That means it will be farming out many of is mundane ...
  18. 'Great Rotation': Fact or Fiction - Analyst Blog

    February 11, 2013
    Domestic stock funds garnered a whopping $21 billion in the initial four weeks of 2013, according to Lipper. This was the ...
  19. Stock Market News for February 5, 2013 - Market News

    February 5, 2013
    Benchmarks retreated from recent highs following weaker-than-expected factory orders and investor concerns about the Euro-zone ...
  20. Earnings Preview: Merck - Analyst Blog

    January 30, 2013
    Merck & Co. Inc. (MRK) is scheduled to report its fourth quarter 2012 results on Feb 1, 2013 before the opening bell. Last ...
  21. Stock Market News for January 30, 2013 - Market News

    January 30, 2013
    Better-than-expected quarterly results once again guided the S&P 500 and the Dow Jones into the green on Tuesday. Strong ...
  22. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  23. MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  24. Pfizer Readies Zoetis For Market

    January 23, 2013
    Pfizer filed further details about its tentative spin-off of Zoetis, its animal health business.
  25. Profits: A Dirty Word

    January 14, 2013
    Every three months, publicly traded companies report their earnings—their profits, or losses. And this quarter, the ...
  26. Stock Market News for January 8, 2013 - Market News

    January 8, 2013
    Investor apprehensions surrounding fourth-quarter earnings dragged benchmarks into negative territory on Monday. Indices ...
  27. Dr. Reddy's Launches Generic Propecia - Analyst Blog

    January 7, 2013
    Dr. Reddy's Laboratories Ltd. (RDY) recently announced that it has launched its generic version of Merck & Co., Inc.'s (MRK) ...
  28. Merck and More Big Movers in Healthcare on December 20, 2012

    December 20, 2012
    The Nasdaq is down 0.4%, the S&P 500 remains relatively unchanged and the Dow has decreased 0.1% after the morning's trading. ...
  29. An End to Drug Patent Woes? - Analyst Blog

    December 14, 2012
    The US Supreme Court will soon hear a case which will determine whether "pay-for-delay" agreements between drug manufacturers ...
  30. Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  31. Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  32. Stock Market News for November 30, 2012 - Market News

    November 30, 2012
    Benchmarks finished in the green propelled by a slew of positive economic reports. GDP expanded more than initially expected, ...
  33. Stock Market News for November 7, 2012 - Market News

    November 7, 2012
    Markets ended in the green yesterday, as uncertainty over the White House race was about to end soon. The election results ...
  34. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  35. Beat and Raise Quarter for Amgen - Analyst Blog

    October 24, 2012
    Amgen (AMGN) continued its strong performance in 2012 with third quarter earnings coming in at $1.66 per share, 23 cents ...
  36. It's Time to Sell These 4 Surging Stocks

    October 19, 2012
    With the S&P 500 surging roughly 25% in the past 12 months, it's been a great time to have full exposure to the stock market. ...
  37. Stock Market News for October 16, 2012 - Market News

    October 16, 2012
    Strong September retail sales data coupled with better-than-expected quarterly results by Citigroup drove the benchmarks ...
  38. Mylan in Neutral Lane - Analyst Blog

    October 10, 2012
    We are maintaining our Neutral recommendation on Mylan Inc. (MYL) with a target price of $26.00. The stock carries a Zacks ...
  39. Vical and Bristol-Myers Ink Deal - Analyst Blog

    September 17, 2012
    Vical Incorporated (VICL) recently signed an agreement with Bristol-Myers Squibb Company (BMY) providing the latter with ...
  40. Novartis Progresses with LCZ696 - Analyst Blog

    August 30, 2012
    Switzerland-based pharmaceutical company, Novartis AG (NVS) recently announced positive phase II data on its pipeline candidate, ...
  41. The Top 10 Most Profitable Companies in America

    August 27, 2012
    Take your mind to 2003. The United States has just sent troops into Iraq, Alex Rodriguez has just swatted 47 home runs for ...
  42. Pfizer Looks To Spin Off Animal Health Unit

    August 15, 2012
    Pfizer has filed plans to sell up to 20% of its animal-health unit in the first half of 2013 to focus on human pharmaceuticals. ...
  43. Europe, Retail Gaining Traction? - Analyst Blog

    August 14, 2012
    Following some decent earnings numbers from a few of the U.S.'s top retailers, we also received good economic data this morning. ...
  44. Ahead of Wall Street - August 14, 2012 - Ahead of Wall Street

    August 14, 2012
    August 14, 2012 Following some decent earnings numbers from a few of the U.S.'s top retailers, we also received good ...
  45. Stock Market News for July 30, 2012 - Market News

    July 30, 2012
    The nation's central bank and the European Central Bank sparked off fresh hopes of economic stimulus among investors that ...
  46. Amgen Beats, Raises Guidance - Analyst Blog

    July 27, 2012
    Amgen (AMGN) continued its strong performance in 2012 with second quarter earnings coming in at $1.82 per share, 31 cents ...
  47. ETF Trading Report: Emerging Market, Industrial ETFs In Focus ...

    July 12, 2012
    American stocks once again finished the day in the red as all the major benchmarks slumped during Thursday's session. The ...
  48. Healthcare Sector's Biggest Movers for July 12, 2012

    July 12, 2012
    The market is currently down, with the Nasdaq decreasing 1.3%, the S&P 500 falling 0.8% and the Dow declining 0.5%. The healthcare ...
  49. What Patent Cliff? Pharma ETFs Continue to Surge - ETF News And ...

    July 10, 2012
    For at least the past few years, investors in the health care segment have been focused in on big pharma and the segment's ...
  50. June's Best Dow Stocks

    June 30, 2012
    The Dow Jones Industrial Average closed June and the second quarter in stellar fashion with an astounding 278-point gain ...
  51. Seeking Safety This Summer

    June 22, 2012
    A defensive stance could be the best offense going into the summer. The consumer staples, healthcare and utility sectors ...
  52. Perrigo in Neutral Lane - Analyst Blog

    June 14, 2012
    We have maintained our Neutral rating on Perrigo Company (PRGO) with a target price of $112.00. Our long-term recommendation ...
  53. Dow 30 Stocks With High Dividends

    June 1, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  54. Eli Lilly Paying Investors To Wait

    May 3, 2012
    The pharmaceutical giant reported decent first quarter results late in April 2012. However, It will likely be some time before ...
  55. Exxon Mobil Staying Energetic

    May 2, 2012
    Exxon Mobil doesn't appear to be having any expansion problems whatsoever.
  56. The 10 Most Overbought Dow Stocks

    May 1, 2012
    Their surprising 2011 outperformance has left many big Dow stocks close to overbought conditions, but several strong performers ...
  57. The Perfect Rx for Your Portfolio

    April 4, 2012
    These three big drug stocks offer attractive yields and relative safety heading into the more challenging summer months, ...
  58. 7 Great Names for Dividend Yield

    March 30, 2012
    Large, dividend-paying equities are good portfolio additions in this low-interest-rate environment, says asset manager Chip ...
  59. 5 Dow 30 Stocks With Huge Dividends

    March 21, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  60. Birth Control Subsidies Slashed: Will Big Pharma Take A Hit?

    March 6, 2012
    Several states have already slashed birth control subsidies. Learn how this will affect pharmaceutical stocks.
  61. Profit-Taking Time for This Drug Stock

    February 29, 2012
    Use this opportunity to step out of this stock while it's in rally mode, and if you want exposure in the sector, put your ...
  62. The Week Ahead: Will Crude Oil Crush the Recovery?

    February 28, 2012
    Select buying opportunities remain, but the combination of rising oil prices and latest deterioration in the financial sector ...
  63. 5 Dow 30 Stocks With Huge Dividends

    February 27, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  64. Pfizer Shrugs Off the Loss Of Lipitor

    February 6, 2012
    Pfizer remains very profitable and has ample cushion to adjust its cost structure to maintain a respectable level of profit ...
  65. Health Care's Highest Yields

    January 30, 2012
    Some of the biggest and highest-yielding drug stocks are declining near attractive buy levels, giving income-oriented investors ...
  66. Diversified Investment Appeal From Novartis

    January 27, 2012
    The healthcare giant reported impressive results in 2011 and offers a reasonable valuation and solid dividends.
  67. The Hot ETF for 2012

    January 11, 2012
    Here's a look at the method behind the picking my annual Hot Hand, so even if the pick misfires, at least you can buy into ...
  68. 5 Dow 30 Stocks With Huge Dividends

    December 22, 2011
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  69. If Pipelines Matter, Novartis Should Be Looking Healthy

    November 30, 2011
    When a company like Novartis comes down the road with a healthy pipeline, the Street seems to respond with worries.
  70. 5 Dow 30 Stocks With Huge Dividends

    November 24, 2011
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  71. Is Third Time The Charm For Gilead?

    November 22, 2011
    Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
  72. Dendreon's Chinese Water Torture

    November 3, 2011
    Dendreon's Provenge continues to shape up as a major disappointment.
  73. Should Pfizer Forget R&D Altogether?

    November 2, 2011
    Pfizer has to convince the Street that it can still grow, but the stock is cheap for now.
  74. Abbott Has Benefited From Its Diversification

    October 25, 2011
    Why is Abbott deciding to break apart?
  75. Protect On The Downside With J&J

    October 21, 2011
    J&J trades at a reasonable forward P/E and offers investors downside protection.
  76. Are We Headed For A Recession?

    October 12, 2011
    The stock market seems to think that the United States is headed for a recession. The economic evidence doesn't yet support ...
  77. The 3 Highest Yielding Pharma Stocks

    September 30, 2011
    Learn more about three large pharmaceutical companies with the highest current yields.
  78. 5 Dow 30 Stocks With Huge Dividends

    September 28, 2011
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  79. Illumina Gets Capped And Cut

    August 4, 2011
    Illumina's sky-high valuation takes a beating on lower guidance.
  80. Why Small May Be Better in Pharma

    July 28, 2011
    Health care’s rebound has been very kind to drugmakers in general, but as Mark Skousen of Turnaround Trader explains ...
  81. 10 Drug Firms to Profit on Biosimilars

    July 28, 2011
    Over the next five years, the market for "biosimilars" is forecast to climb to $10 billion worldwide, as many brand-name ...
  82. Three Safe Sectors For The Summer

    July 11, 2011
    With uncertainty beginning to creep back into the markets, investors may want to take a defensive posture.
  83. 4 Dow 30 Stocks With Huge Dividends

    July 6, 2011
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  84. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  85. Johnson & Johnson Surrenders In Stents

    June 17, 2011
    JNJ makes a tough and surprising, but ultimately wise, decision.
  86. Lipitor: Pfizer's Loss Is Watson's Gain

    June 10, 2011
    With Lipitor coming off its patent soon, there are a couple of drug companies looking to cash in on sales of the generic ...
  87. Novo Nordisk Still One Of The Best Around

    May 3, 2011
    Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
  88. April's Dow 30 Winners and Losers

    May 2, 2011
    See the best and worst performing DJIA stocks from April 2011!
  89. 2 Stocks With Room To Raise Dividends

    April 13, 2011
    These two decent dividend-paying stocks are more attractive than they may seem on the surface.
  90. Irish Stocks Present Possible Value Play

    March 9, 2011
    Despite its fiscal woes, Ireland' tech story could ultimately become its saving grace.
  91. Novavax Gets A Booster Shot From The Government

    March 1, 2011
    Novavax gets a sizable contract from the government that will largely fund its remaining clinical trials for flu vaccines.
  92. 5 Oversold Stocks To Watch

    February 23, 2011
    Let's take a look at a few stocks that have recently entered oversold territory because these could be candidates for a short-term ...
  93. Attack Of The Mega-Caps

    February 22, 2011
    These large companies can add protection for investors, in case there are some missteps in the current economic recovery.
  94. Becton Dickinson Ready For A Breather

    February 11, 2011
    Becton Dickinson's stock could pause for a breather and dip back to levels where the risk/reward tradeoff is more compelling.
  95. January's Dow 30 Winners and Losers

    February 1, 2011
    See the best and worst performing DJIA stocks from January 2011!
  96. MannKind And The FDA - Here We Go Again

    January 20, 2011
    MNKD got another FDA setback in its attempts to bring inhaled insulin to the market.
  97. Forest Labs Has Wood To Chop

    January 19, 2011
    Will Forest be able to plug a gaping hole in its future revenue?
  98. Large Cap Dividend Stocks For 2011

    December 17, 2010
    Investors interested in yield for the new year might want to consider a package of solid, stable, large cap stocks which ...
  99. Pfizer Ready To Create Value

    December 15, 2010
    Overall, Pfizer is a company with a cheap stock price, earnings power and numerous options to reward shareholders.
  100. Five Strong Socially Responsible Stocks

    December 15, 2010
    Making money in the market shouldn't prevent you from sleeping at night. Find out how to keep your conscience clean and wealth ...
  101. 7 Reasons To Pick ETFs Over Stocks

    November 1, 2010
    As a cost-effective way to achieve a broadly diversified portfolio, including hard-to-own (but worthwhile) assets, ETFs are ...
  102. The Good And Bad Of DuPont's Strength

    October 28, 2010
    DuPont's success confirms an economic recovery, but raises the spectre of inflation.
  103. Should Investors Take A Chance On Savient?

    October 26, 2010
    Savient's inability to sell itself puts almost everything about the company's value in flux.
  104. 5 Dow 30 Stocks With Huge Dividends

    October 1, 2010
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  105. Bristol-Myers Pays A Premium For Its Partner

    September 10, 2010
    Bristol-Myers is paying a lot, but a successful HCV franchise could be worth much more.
  106. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  107. AmerisourceBergen Continues to Impress

    July 28, 2010
    This drug distribution company is reaping the benefits of drug patent expiration and the government's new focus on healthcare.
  108. BP's Management: Will A Change Do The Company Good?

    July 27, 2010
    BP announced that it will replace CEO Tony Haward. How will investors take the news?
  109. Mega-Cap Value Stocks

    July 12, 2010
    The major US stocks are trading at valuation levels not seen in over two decades and a few of the big-cap names are now attractive ...
  110. Playing Big Pharma With CROs

    July 6, 2010
    Investors looking to play the growth in R&D spending for human drugs should consider CROs.
  111. Pharmaceuticals With Big Returns

    June 22, 2010
    These intriguing Pharmaceuticals currently have big returns.
  112. Stocks That Protect Against Deflation

    June 21, 2010
    Although recent data suggests prices may be falling, inflation may still take over in the long term due to the excess liquidity ...
  113. Amgen's New Double-Play Drug

    June 8, 2010
    Amgen hopes for a boost in revenue from their just-approved multi-purpose drug, Prolia.
  114. Big Pharma's On Sale

    June 4, 2010
    Stocks of some of the large pharmaceutical companies are now available at attractive prices.
  115. Invest In The Magazine Portfolio

    May 6, 2010
    Just for fun, I went through advertisers in Canadian House and Home. Despite being a Canadian magazine, well-known names ...
  116. Pfizer Delivers A Healthy Quarter

    May 6, 2010
    Despite forecasting adjusted earnings of over $2 a share for 2010, Pfizer shares remain at $17.
  117. The S&P 500's Cheapest Stocks

    April 27, 2010
    Everybody loves a bargain, but finding a true bargain in the stock market can be a difficult task.
  118. Dividends With Earnings Growth

    April 23, 2010
    These healthcare and pharma companies have a solid dividend and increasing earnings over the last five years.
  119. Lilly's Top-Line Predicament

    April 21, 2010
    Eli Lilly will have more than $5 billion in annual free cash flow over the next few years to try and stem its top-line predicament.
  120. Big Names To Watch

    April 20, 2010
    We look at companies with long operating histories and consistent earnings that will help investors during a market pullback.
  121. Four Stocks With Low P/Es And Great Dividends

    March 15, 2010
    These four are selling for cheap and paying out big.
  122. Best Stocks In February 2010

    March 4, 2010
    The best performing stocks in the S&P 500 in February 2010 benefited from takeover activity and positive earnings surprises.
  123. Dogs Of The Dow For 2010

    January 21, 2010
    Will this well-heeled strategy pay off in the next 12 months?
  124. 2009's "Dogs of the Dow"

    December 31, 2009
    Was there any bite to the Dogs of the Dow strategy last year?
  125. A Review Of The Drug Makers Of 2009

    December 29, 2009
    Corporate deal-making was the name of the big pharma game in 2009 and will likely continue into the new year.
  126. AmerisourceBergen Profitably Pushing Drugs

    November 5, 2009
    AmerisourceBergen should continue to grows its top line modestly and generate substantial cash flow for shareholders.
  127. Bristol Myers: A Good Pill To Swallow?

    August 17, 2009
    A nice dividend yield shouldn't be the only reason to invest in a company, but it is a nice bonus.
  128. A Rocky Week For Abbott Labs

    July 3, 2009
    This healthcare company has seen better weeks, but it's still too early to tell if recent bad news will pummel the stock.
  129. It Pays To Advertise

    June 29, 2009
    During hard times, some companies reduce advertising while others increase it. Which method is the most effective?
  130. Four Breakout Biotech Stocks

    June 12, 2009
    These four biotech stocks are currently on the upswing.
  131. Is Pfizer What The Doctor Ordered Or Bad Medicine?

    April 30, 2009
    Explore Pfizer, its earnings and its recent acquisition deal.
  132. Big Pharma's Buying Spree

    April 24, 2009
    A look at recent merger and acquisition activity in the pharmaceutical sector and possible opportunities if the trend continues.
  133. Johnson & Johnson Should Return To Form

    April 16, 2009
    Though J&J hasn't been delivering consistent, steady growth as of late, this company should prove healthy in the future.
  134. March Mid Cap Losers

    April 7, 2009
    The five worst performing mid cap stocks in March were in a range of industries, and had little in common except missing ...
  135. Abbott Labs A Solid Pharma Stock

    April 3, 2009
    Abbott Labs has continued to perform solidly as a business and looks poised with its product line to keep going strong.
  136. Pharmaceuticals: A Prescription For Opportunity

    March 17, 2009
    Deal flow in the drug industry as companies look to improve their product lines.
  137. Invest In The Original S&P 500

    February 18, 2009
    An amazing number of the original companies in the S&P 500 index are still trading. I'll pick out some interesting choices ...
  138. Bristol-Myers Pays Healthy Dividends

    February 12, 2009
    Bristol-Myers is among five companies with a great forward annual dividend yield.
  139. Betting On Job Losses

    February 5, 2009
    The current job losses aren't pretty. As investors, we have ways to play this.
  140. Abbott: The New Healthcare Bellwether

    January 27, 2009
    The healthcare industry fell 24.5% in 2008. Abbott fell 4%. Any questions?
  141. Forest Labs Faces Patent Expirations

    January 23, 2009
    This pharma faces patent expirations on its two key drugs, but its valuation reflects these risks and the firm has appealing ...
  142. No More Tears For Johnson & Johnson

    January 23, 2009
    Its wide range of products and international exposure give this stock a positive long-term outlook.
  143. Sigma-Aldrich's New Tech Proves Recession-Proof

    October 29, 2008
    Sigma-Aldrich's Q3 earnings were steady, and with downside protection a major theme in the markets these days, it's hard ...
  144. Missing Forest Labs For The Trees

    October 27, 2008
    Forest Labs is facing a lull in its pipeline, but prior lulls have been good buying opportunities.
  145. How Much Vigor In Invitrogen?

    October 27, 2008
    Invitrogen is in the right space, but does management have the right plan?
  146. Earnings Roundup: General Dynamics, Merck, Reynolds

    October 23, 2008
    We go beyond the numbers to dissect what's really happening at General Dynamics, Merck and Reynolds American.
  147. 10 Blue Chips On The Outs

    October 8, 2008
    The market has taken down stocks of all caliber, and these formerly sturdy blue chip stocks are due another look as we wait ...
  148. What Imclone Means To Eli Lilly

    October 7, 2008
    Eli Lilly expands its cancer offering with the acquisition of Imclone. Can the union boost Eli Lilly's floundering stock ...
  149. Winners Of The Dow Dog Show For September 3

    September 3, 2008
    Let the Dogs of the Dow strategy point you to potential winners. This week's best of breed is DuPont.
  150. The Contrarian Case For Pfizer

    August 29, 2008
    Pfizer has plenty of free cash for R&D or acquisitions, and its low forward P/E provides a solid margin of safety.
  151. Winners Of The Dow Dog Show For August 27

    August 27, 2008
    The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to rise. This ...
  152. Winners Of The Dow Dog Show For August 19

    August 19, 2008
    The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to go up. Best ...
  153. Winners Of The Dow Dog Show For August 11

    August 11, 2008
    The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to go up. Pfizer ...
  154. Amgen's $30 Billion Riddle - Biotech Or Big Pharma?

    August 7, 2008
    Amgen's valuations seem too low given recent good news and earnings results. We explore what its new benchmark P/E should ...
  155. Winners Of The Dow Dog Show For July 29

    July 29, 2008
    The Dogs of the Dow strategy lets investors find undervalued blue chips. This week the best of breed is GE.
  156. Winners Of The Dow Dog Show For July 17

    July 17, 2008
    The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to go up. We ...
  157. Winners Of The Dow Dog Show

    June 20, 2008
    The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to go up. We ...
  158. Pfizer: What's In Your Pipeline?

    April 29, 2008
    If your looking to add value to your portfolio consider Pfizer for its sound fundamentals and enticing dividend.
  159. Leap Of Faith Healing (MEDX, PDLI, AMLN)

    August 8, 2007
    Make the leap with three pharmaceutical companies who require investor courage but could provide a healthy return.
  160. Johnson & Johnson Looking Healthy (JNJ)

    August 7, 2007
    JNJ stock is strong and vigorous thanks to the company's line of essential products and stellar financials.
  161. Mulling Mid-Cap Medicine (SEPR, MYL, KG)

    July 9, 2007
    A look at three mid-cap pharmaceutical companies with three very different approaches to business.
  162. Turning The Rumor Mill (DELL, TRMP, NFLX, MRK)

    June 12, 2007
    A roundup of the week's popular news stories and market rumors.
  163. Ultimate Headache Relief (BAY)

    May 17, 2007
    Investors seeking big pharma exposure often confine themselves to the United States, but the best drug company just might ...
  164. Up on Amgen (AMGN)

    April 30, 2007
    Amgen shares are in a rut, and that could signal opportunity for investors.
  165. Johnson & Johnson Blows Away Q1 (JNJ)

    April 20, 2007
    J&J beat its Q1 consensus number with ease, so where is the stock is headed from here?
  166. Generic Manufacturers Go After Big Pharma

    March 14, 2007
    Generic drug manufacturers continue pose a potent threat to the established "big pharma" companies.
  167. Schering's Big Deal (SGP)

    March 13, 2007
    An inside look at Schering Plough's big deal to buy Organon BioSciences.
  168. Two Big Names With Big Upside (PG, MRK)

    March 2, 2007
    A look inside two prominent stocks that offer good potential even in the currently bearish market conditions.
  169. Panic Begets Opportunity (JNJ)

    March 1, 2007
    In the wake of the recent market sell-off, shares of the always stable JNJ appear to be a good value play.
  170. P/E Ratios Still Matter

    February 1, 2007
    High P/E stocks are almost always more glamorous than their low P/E counterparts, but are they more profitable?
  171. Pfizer's Down, But Not Out (PFE)

    January 24, 2007
    While Pfizer's current issues are cause for concern, the company's long-term plans make it worth a second look.
  172. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider.
  173. Winners and Losers - October 30th - November 3rd (RNAI, TCC, ...

    November 3, 2006
    A look at some of the market's winners and losers for the week of October 30th.
  174. A Value Stock In A Growth Industry (BVF)

    September 20, 2006
    Uncertainty surrounding patent protection of antidepressant Wellbrutin makes Biovail a compelling investment.
  175. Consolidation Looks To Be In The Cards (MRK, BMY, SGP)

    September 18, 2006
    A look into the merger possiblities of three of the drug industry's major players.
  176. Cadbury's Sticky Mess (CSG)

    August 18, 2006
    Can the world’s largest confectionery maker avoid taking a potential product liability hit?
  177. A Hot Sector?

    December 21, 2005
    Another example of a sector that "falls between the cracks" - elearning.
  178. A Look at Economic Moats - Part 2

    November 23, 2005
    In this piece we'll explore different types of economic moats.
Investing News
  1. Outside the Box: Hoisington Investment Mgmt Review and Outlook, Q1 2014

    Outside the Box: Hoisington Investment Management Quarterly Review and Outlook, First Quarter ...
  2. Why Stick With Energy Stocks? (Hint: Geopolitical Risk)

    By most fundamental measures, oil prices should be declining. Russ explains why they’re on ...
  3. Bad Investor Behavior: Overemphasizing Experience

    Behavioral finance researchers have discovered that our personal experiences disproportionately ...
  4. Thoughts From The Frontline: Every Central Bank For Itself

    Thoughts from the Frontline: Every Central Bank for Itself
  5. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  6. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
Trading Center